Skip Navigation


JAC Advance Access originally published online on February 18, 2008
Journal of Antimicrobial Chemotherapy 2008 61(5):1182-1183; doi:10.1093/jac/dkn065
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/5/1182    most recent
dkn065v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Werner, G.
Right arrow Articles by Klare, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werner, G.
Right arrow Articles by Klare, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient

Guido Werner1,*, Sabine Gfrörer2,{dagger}, Carola Fleige1, Wolfgang Witte1 and Ingo Klare1

1 Robert Koch Institute, Wernigerode Branch, Burgstr. 37, D-38855 Wernigerode, Germany 2 Institute for Laboratory Medicine, Vinzenz von Paul Clinics, Marienhospital Stuttgart, Böheimstr. 37, D-70199 Stuttgart, Germany

* Corresponding author. Tel: +49-3943-679210; Fax: +49-3943-679207; E-mail: wernerg@rki.de

Keywords: reserpine , omeprazole , glycylcyclines , tetX

The first 10% of the full text of this article appears below.

Sir,

Tigecycline is a member of the new group of glycylcyclines and a promising new antibiotic of last resort, active against many bacteria including Enterococcus spp.1,2 Tigecycline acts in a similar way to tetracyclines by binding to the 30S subunit of the bacterial ribosome and thus inhibiting protein biosynthesis;1 however, different binding capacities and kinetics also allow activity against tetracycline-resistant bacteria.1 Enterococcal isolates displaying MICs of tigecycline of ≤0.25 mg/L are considered susceptible.3 The epidemiological cut-off value (breakpoint) for tigecycline is >0.5 mg/L for enterococci.3 Here, we report the first . . . [Full Text of this Article]


   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
E. Malli, I. Spiliopoulou, F. Kolonitsiou, Ch. Neocleous, D. Klapsa, K. Pantelidi, M. Panopoulou, S. Grapsa, E. Alepopoulou, I. Neonakis, et al.
In vitro activity of tigecycline against Gram-positive cocci: a multicentre study in Greece
J. Antimicrob. Chemother., November 1, 2008; 62(5): 1158 - 1160.
[Full Text] [PDF]